Martinsried/Munich, February 11, 2008. Within the scope of the funding program “KMU-innovativ: Biotechnologie - BioChance” MediGene AG (Frankfurt, Prime Standard: MDG) will receive a research grant totaling approximately 600,000 Euros, paid by the Federal Ministry of Education and Research (BMBF = Bundesministerium für Bildung und Forschung) over a period of three years.
The „BioChancePlus” competition shall boost the innovation potential of small and medium-sized enterprises in the field of top-level research. Another purpose of the funding program is to strengthen the technological foundation of biotech companies in order to provide a basis for their sustained growth. MediGene’s research activities in the field of immunology fufill the criteria „excellence“, „innovation level“, and „significance of the company’s contribution to resolving current socially relevant problems”, and will therefore be funded.
Dr. Peter Heinrich, Chief Executive Officer of MediGene AG, comments: „We are proud that our research project was chosen for this renowned funding program by an independent academic committee. This underlines our company’s expertise in research. Government funding of innovative research and development activities is a very important and positive signal for the biotech site Germany.”
